News & Updates

The COVID-19 pandemic has worsened the adherence to ocular hypotensive medication among patients with primary open-angle glaucoma (POAG), according to a study. Such reduction is potentially driven by lower psychometric measures of resilience and more confrontational coping strategies.

Receipt of a booster dose of the COVID-19 vaccine reduces the risk of breakthrough COVID-19 infections* compared to full vaccination only, particularly among individuals without immunosuppressed/compromised conditions (ISC), according to a US study presented at CROI 2022.

A knowledge gap exists on the effects of direct oral anticoagulants (DOACs), but most nonvalvular atrial fibrillation (NVAF) patients with liver disease still begin treatment with these medications, particularly apixaban and rivaroxaban, a study has found.

Use of antihypertensive medications is associated with the incidence of psoriasis, reports a study. Beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers (CCBs), and thiazide diuretics result in an increased risk of psoriasis.

The combination of olaparib and abiraterone in the first-line setting improved radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC), results of the phase III PROpel trial showed.

Treatment with roxadustat leads to significant improvements in renal anaemia among patients with chronic kidney disease (CKD) by increasing haemoglobin (Hb) level and iron metabolism, according to a recent study. However, the risk of serious adverse events (AEs) during treatment must be considered.